Nexien Biopharma Stock Buy Hold or Sell Recommendation
| NXEN Stock | USD 0.01 0.01 25.00% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Nexien Biopharma is 'Sell'. The recommendation algorithm takes into account all of Nexien Biopharma's available fundamental, technical, and predictive indicators you will find on this site.
Check out Nexien Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Nexien and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Nexien Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income.
Nexien |
Execute Nexien Biopharma Buy or Sell Advice
The Nexien recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Nexien Biopharma. Macroaxis does not own or have any residual interests in Nexien Biopharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Nexien Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | OK | Details | |
Volatility | Out of control | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Nexien Biopharma Trading Alerts and Improvement Suggestions
| Nexien Biopharma is way too risky over 90 days horizon | |
| Nexien Biopharma has some characteristics of a very speculative penny stock | |
| Nexien Biopharma appears to be risky and price may revert if volatility continues | |
| Nexien Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Nexien Biopharma currently holds 221.73 K in liabilities with Debt to Equity (D/E) ratio of 0.36, which is about average as compared to similar companies. Nexien Biopharma has a current ratio of 0.5, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Nexien Biopharma until it has trouble settling it off, either with new capital or with free cash flow. So, Nexien Biopharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Nexien Biopharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Nexien to invest in growth at high rates of return. When we think about Nexien Biopharma's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (626.36 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Nexien Biopharma currently holds about 116.9 K in cash with (75.14 K) of positive cash flow from operations. | |
| Roughly 54.0% of Nexien Biopharma outstanding shares are owned by corporate insiders |
Nexien Biopharma Returns Distribution Density
The distribution of Nexien Biopharma's historical returns is an attempt to chart the uncertainty of Nexien Biopharma's future price movements. The chart of the probability distribution of Nexien Biopharma daily returns describes the distribution of returns around its average expected value. We use Nexien Biopharma price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Nexien Biopharma returns is essential to provide solid investment advice for Nexien Biopharma.
| Mean Return | 4.67 | Value At Risk | -47.71 | Potential Upside | 59.09 | Standard Deviation | 34.22 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Nexien Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Nexien Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Nexien Biopharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Nexien Biopharma's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Nexien pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 4.28 | |
β | Beta against Dow Jones | 3.19 | |
σ | Overall volatility | 34.74 | |
Ir | Information ratio | 0.13 |
Nexien Biopharma Volatility Alert
Nexien Biopharma is showing large volatility of returns over the selected time horizon. Nexien Biopharma is a penny stock. Although Nexien Biopharma may be in fact a good investment, many penny pink sheets are subject to artificial price hype. Make sure you completely understand the upside potential and downside risk of investing in Nexien Biopharma. We encourage investors to look for signals such as message board hypes, claims of breakthroughs, email spams, sudden volume upswings, and other similar hype indicators. We also encourage traders to check biographies and work history of company officers before investing in instruments with high volatility. You can indeed make money on Nexien instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Nexien Biopharma Fundamentals Vs Peers
Comparing Nexien Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Nexien Biopharma's direct or indirect competition across all of the common fundamentals between Nexien Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Nexien Biopharma or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Nexien Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Nexien Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Nexien Biopharma to competition |
| Fundamentals | Nexien Biopharma | Peer Average |
| Return On Equity | -40.7 | -0.31 |
| Return On Asset | -5.99 | -0.14 |
| Current Valuation | 2.58 M | 16.62 B |
| Shares Outstanding | 62.77 M | 571.82 M |
| Shares Owned By Insiders | 54.17 % | 10.09 % |
| Price To Book | 205.41 X | 9.51 X |
| EBITDA | (563.99 K) | 3.9 B |
| Net Income | (626.36 K) | 570.98 M |
| Cash And Equivalents | 116.9 K | 2.7 B |
| Total Debt | 221.73 K | 5.32 B |
| Debt To Equity | 0.36 % | 48.70 % |
| Current Ratio | 0.51 X | 2.16 X |
| Book Value Per Share | (0) X | 1.93 K |
| Cash Flow From Operations | (75.14 K) | 971.22 M |
| Earnings Per Share | (0.01) X | 3.12 X |
| Number Of Employees | 6 | 18.84 K |
| Beta | 1.48 | -0.15 |
| Market Capitalization | 1.95 M | 19.03 B |
| Total Asset | 124.52 K | 29.47 B |
| Z Score | -8.4 | 8.72 |
| Net Asset | 124.52 K |
Nexien Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Nexien . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Daily Balance Of Power | (9,223,372,036,855) | |||
| Rate Of Daily Change | 0.75 | |||
| Day Median Price | 0.015 | |||
| Day Typical Price | 0.015 | |||
| Price Action Indicator | (0) | |||
| Period Momentum Indicator | (0.01) | |||
| Relative Strength Index | 77.8 |
About Nexien Biopharma Buy or Sell Advice
When is the right time to buy or sell Nexien Biopharma? Buying financial instruments such as Nexien Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Nexien Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Drugs Thematic Idea Now
Drugs
Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. The Drugs theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Drugs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Nexien Pink Sheet
Nexien Biopharma financial ratios help investors to determine whether Nexien Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nexien with respect to the benefits of owning Nexien Biopharma security.